Alltrna, a Flagship Pioneering company focused on transfer RNA (tRNA) biology and therapeutics, has received approval to initiate a Phase I clinical trial of its lead candidate AP003 in healthy volunteers in Australia. The study has been cleared under the Therapeutic Goods Administration’s (TGA) Clinical Trial Notification (CTN) scheme following review by the Human Research Ethics Committee (HREC).

AP003 is a chemically modified, engineered tRNA therapeutic designed to restore full-length protein production by inserting the correct amino acid at premature termination codons (PTCs). The therapy represents a novel approach aimed at treating genetic disorders caused by stop codon mutations, often referred to as Stop Codon Disease.

This marks the first time an engineered tRNA therapy will be tested in humans, positioning the study as a significant milestone in the development of next-generation genetic medicines. The Phase I trial will assess the safety and pharmacokinetics of single ascending doses of AP003 in healthy volunteers, with findings expected to guide further clinical development in patient populations.

According to the company, preclinical studies have demonstrated AP003’s ability to restore full-length protein expression and functional activity across disease models driven by shared PTCs. The therapy has also shown a safety profile consistent with established oligonucleotide and lipid nanoparticle-based treatments, supporting its progression into clinical evaluation.

Company executives highlighted that the trial will help establish foundational clinical data for this new therapeutic modality, which could potentially address multiple genetic diseases sharing the same mutation mechanism.

The study is expected to generate key safety and pharmacokinetic insights, paving the way for future trials targeting patients with limited or no treatment options for underlying genetic conditions.